From: Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma
Patient no. | Age | Gender | Dose of peptide (mg) | Number of vaccination | Adverse events | DTH skin test | Evaluation of CT images |
---|---|---|---|---|---|---|---|
1 | 69 | M | 0.1 | 1 | - | - | PD |
2 | 32 | M | 0.1 | 3 | - | - | PD |
3 | 21 | F | 0.1 | 6 | - | - | PD |
4 | 21 | M | 1.0 | 6 | - | - | PD |
5 | 39 | F | 1.0 | 6 | Fever | - | NC |
6 | 26 | M | 1.0 | 4 | - | - | PD |